Latest Period
Q1 2026
Security Snapshot
Caribou Biosciences, Inc. - Common Stock (CRBU) Institutional Ownership
CUSIP: 142038108
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026
Institutions Reporting
135
Shares (Excl. Options)
37,842,123
Price
$1.90
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CRBU on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 37,842,123
- Total 13F value
- $71,332,410
- Portfolio coverage rank
- 0%
- Share change
- +827,391
- Value change
- +$2,012,687
- Number of holders
- 135
- Shares outstanding
- 92,189,700
- SEC-reported price per share
- $2.20
- Insider filing price
- $2.20
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CRBU - Caribou Biosciences, Inc. - Common Stock is tracked under CUSIP 142038108.
- 135 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 121 to 135 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $58,834,815 to $71,332,410.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 135 institutions filings for Q1 2026.
Security key
142038108
Latest holder period
Q1 2026
13F holders
135
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
CRBU full holder history
Caribou Biosciences, Inc. SEC filings
Caribou Biosciences, Inc. company facts
Caribou Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 142038108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
CRBU
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Haurwitz Rachel E. | 5% | $4,008,603 | 4,716,003 | Rachel E. Haurwitz | 22 Apr 2025 | |||
| VANGUARD GROUP INC | 4.9% | $3,843,727 | 4,522,032 | The Vanguard Group | 31 Mar 2025 | |||
| BANK OF AMERICA CORP /DE/ | 2.2% | $1,658,405 | 1,951,065 | BANK OF AMERICA CORP /DE/ | 31 Dec 2024 | |||
| BlackRock, Inc. | 2% | -69% | $2,323,180 | -$5,591,740 | 1,843,794 | -71% | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Mar 2026, 135 institutional investors reported holding 37,842,123 shares of Caribou Biosciences, Inc. - Common Stock (CRBU). This represents 41% of the company’s total 92,189,700 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
35%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Pfizer Inc | 5.1% | 4,690,431 | 0% | 3.5% | $8,348,967 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 3,767,228 | 0% | 0% | $7,157,733 |
| RENAISSANCE TECHNOLOGIES LLC | 2.8% | 2,590,497 | +58% | 0.01% | $4,921,944 |
| Kynam Capital Management, LP | 2.7% | 2,503,302 | 0% | 0.3% | $4,756,274 |
| BlackRock, Inc. | 2.3% | 2,143,085 | +0.1% | 0% | $4,071,862 |
| TWO SIGMA INVESTMENTS, LP | 1.9% | 1,759,934 | +73% | 0% | $3,343,875 |
| BANK OF AMERICA CORP /DE/ | 1.4% | 1,297,167 | +31% | 0% | $2,464,618 |
| Aberdeen Group plc | 1.3% | 1,212,541 | -13% | 0% | $2,303,828 |
| MARSHALL WACE, LLP | 1.3% | 1,205,668 | +37% | 0% | $2,290,770 |
| MILLENNIUM MANAGEMENT LLC | 1.2% | 1,074,421 | +40% | 0% | $2,041,400 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 1,017,959 | +4.2% | 0% | $1,934,941 |
| PFM Health Sciences, LP | 1% | 957,787 | 0% | 0.19% | $1,819,795 |
| MACKENZIE FINANCIAL CORP | 1% | 942,786 | 0% | $1,791,293 | |
| ACADIAN ASSET MANAGEMENT LLC | 1% | 925,039 | +1449% | 0% | $1,752,000 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.91% | 836,903 | -19% | 0% | $1,590,116 |
| FMR LLC | 0.79% | 723,959 | -0.28% | 0% | $1,375,522 |
| DIMENSIONAL FUND ADVISORS LP | 0.73% | 673,200 | -33% | 0% | $1,278,102 |
| MAVERICK CAPITAL LTD | 0.71% | 652,542 | 0% | 0.01% | $1,239,830 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.61% | 559,642 | +0.72% | 0% | $1,063,320 |
| Cambridge Investment Research Advisors, Inc. | 0.59% | 547,014 | -6% | 0% | $1,039,000 |
| VANGUARD FIDUCIARY TRUST CO | 0.56% | 520,118 | 0% | 0% | $988,224 |
| GSA CAPITAL PARTNERS LLP | 0.52% | 480,724 | +29% | 0.06% | $913,000 |
| 72 Investment Holdings, LLC | 0.51% | 474,067 | 0% | 1.8% | $900,727 |
| STATE STREET CORP | 0.46% | 423,263 | 0% | 0% | $804,200 |
| GOLDMAN SACHS GROUP INC | 0.41% | 376,589 | -23% | 0% | $715,519 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
Q1 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 37,842,123 | $71,332,410 | +$2,012,687 | $1.90 | 135 |
| 2025 Q4 | 37,003,216 | $58,834,815 | -$1,172,078 | $1.59 | 121 |
| 2025 Q3 | 37,024,074 | $86,267,579 | -$6,898,753 | $2.33 | 115 |
| 2025 Q2 | 40,657,539 | $51,233,181 | -$11,182,668 | $1.26 | 128 |
| 2025 Q1 | 50,124,474 | $45,767,240 | -$8,735,404 | $0.91 | 127 |
| 2024 Q4 | 58,137,691 | $92,442,260 | +$1,344,135 | $1.59 | 130 |
| 2024 Q3 | 52,230,454 | $102,372,092 | -$1,215,533 | $1.96 | 124 |
| 2024 Q2 | 53,030,028 | $86,964,603 | -$69,072,988 | $1.64 | 136 |
| 2024 Q1 | 66,748,618 | $342,979,667 | -$13,445,660 | $5.14 | 149 |
| 2023 Q4 | 69,081,626 | $395,824,161 | -$5,845,565 | $5.73 | 143 |
| 2023 Q3 | 70,779,287 | $338,477,161 | +$132,380,976 | $4.78 | 126 |
| 2023 Q2 | 43,715,651 | $185,309,815 | -$6,639,016 | $4.25 | 117 |
| 2023 Q1 | 44,984,864 | $238,314,447 | +$6,834,942 | $5.31 | 126 |
| 2022 Q4 | 43,609,398 | $273,911,420 | -$3,252,217 | $6.28 | 132 |
| 2022 Q3 | 43,252,045 | $456,982,599 | +$65,340,908 | $10.55 | 114 |
| 2022 Q2 | 37,333,019 | $202,972,596 | +$14,914,954 | $5.43 | 116 |
| 2022 Q1 | 34,952,083 | $321,058,661 | +$23,111,728 | $9.18 | 103 |
| 2021 Q4 | 30,588,325 | $457,556,044 | -$490,819 | $15.09 | 90 |
| 2021 Q3 | 29,587,281 | $693,431,752 | +$646,473,752 | $23.87 | 86 |